A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy

Philip L Lorenzi1, Sofie Claerhout2, Gordon B Mills2

  • 1Department of Bioinformatics and Computational Biology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.

Autophagy
|June 7, 2014
PubMed

Insights

This study compiles a comprehensive inventory of autophagy modulators, identifying 739 proteins and 385 chemicals. This resource aids in understanding autophagy

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncology

Background:

  • Autophagy plays a dual role in cancer, exhibiting both tumor-suppressive and tumor-promoting functions.
  • Both stimulating and inhibiting autophagy can lead to cancer cell death, highlighting its complex involvement in cancer.
  • Specific genes and proteins are linked to autophagy with both positive and negative associations in cancer progression.

Purpose of the Study:

  • To create a comprehensive, curated inventory of autophagy modulators.
  • To provide a foundation for analyzing the complexities of autophagy in cancer.
  • To guide the development of novel autophagy-targeted cancer therapies.

Main Methods:

  • Integrated data from published siRNA screens.
  • Utilized multiple pathway analysis algorithms.
  • Performed extensive, manually curated text-mining of scientific literature.

Main Results:

  • Compiled an inventory of 739 proteins involved in autophagy modulation.
  • Identified 385 chemicals, including drugs, small molecules, and metabolites, that modulate autophagy.
  • Analyzed the sources of information and their interrelationships due to the early stage of autophagy research.

Conclusions:

  • The curated inventory provides a basis for further research into autophagy's role in cancer.
  • Understanding autophagy modulators is crucial for developing targeted cancer therapies.
  • Novel strategies for targeting autophagy in cancer treatment are discussed.

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K